BioSpace News Archive

Survival benefit observed in two treatment settings of previously treated non-small lung cancer patients

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced data from TG-1701, the Company’s investigational once-daily, oral BTK inhibitor, as a monotherapy and as a triple therapy in combination with ublituximab

The Association of Community Cancer Centers (ACCC) today announced the launch of the ACCC Community Oncology Research Institute (ACORI), building on its existing mission to close the gap in cancer research through optimal community oncology partnerships.

Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) today announced that it has entered into an exclusive, global license agreement with Akebia Therapeutics, Inc., a leading biopharmaceutical company focused on kidney disease, for the development and commercialization of praliciguat, an oral sGC stimulator.

Delix Therapeutics (the “Company”), a preclinical neuroscience company developing novel disease-modifying therapeutics for serious psychiatric and neurological conditions, today announced the inaugural members of its Scientific and Strategic Advisory Board.

UroGen Pharma Ltd. a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, announced the grants of inducement restricted stock units to eleven new employees in connection with their employment with UroGen.

Oral presentation highlighting extended follow-up data from phase 1 study in patients with locally advanced or metastatic TKI-resistant, EGFR-mutated NSCLC shows promising clinical activity Data from this study informed the design of the recently initiated pivotal HERTHENA-Lung01 trial in similar patient population

Whole transcriptome analysis of ER+ breast cancers showed no substantial difference in gene expression between tumors from women younger than 50 and women older than 50 Whole transcriptome analysis confirms that genomic expression profiles from BluePrint ER+ Basal tumors and ER- Basal tumors are very similar, providing clinically actionable information to guide neoadjuvant treatment decisions

DarioHealth Corp. (NASDAQ: DRIO), a leader in the global digital therapeutics (DTx) market, announced today it will be presenting results of a new study at the 14th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD 2021; June 2-5, 2021).

TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, today presented updated data from the Company’s Phase 1 study of TJ004309 and Tecentriq® (atezolizumab) at the American Society of Clinical Oncology (ASCO) virtual annual meeting.